ΠΑΝΕΠΙΣΤΗΜΙΟ ΙΩΑΝΝΙΝΩΝ. Εξατοµικευµένη αντιαιµοπεταλιακή αγωγή. Ποιο είναι το µέλλον?
|
|
- Willis Adams
- 6 years ago
- Views:
Transcription
1 ΠΑΝΕΠΙΣΤΗΜΙΟ ΙΩΑΝΝΙΝΩΝ ΕΡΕΥΝΗΤΙΚΟ ΚΕΝΤΡΟ ΑΘΗΡΟΘΡΟΜΒΩΣΗΣ Εξατοµικευµένη αντιαιµοπεταλιακή αγωγή. Ποιο είναι το µέλλον? Αλέξανδρος Δ. Τσελέπης, MD, PhD Καθηγητής Βιοχηµείας - Κλινικής Χηµείας
2 Disclosures None
3 Clopidogrel Resistance Response variability Jaremo P. J Intern Med. 2002; 252:
4 Clopidogrel resistance CYP2C19*1/*2 CYP2C19*1/*1 Good metabolizer Intermediate metabolizer Poor metabolizer
5 Residual Platelet Reactivity High Residual Platelet Reactivity Low Residual Platelet Reactivity HRPR LRPR 10 µμ ADP 30 days 30 days 5 days 5 days Before treatment Before treatment Kalantzi KI, et al. J Thromb Haemost. 2011;9: Kalantzi KI, et al. Platelets. 2012; In Press
6 Clopidogrel Resistance Kaplan-Meier analysis for the cumulative incidence of stent Thrombosis and for the composite of death or stent thrombosis Sibbing D, et al. J Am Coll Cardiol 2009;53:849 56
7 Hazard for early stent thrombosis increases with higher post-treatment platelet aggregation Geisler T, et al. Eur Heart J. 2010
8 Metabolism of ADP P2Y12 Antagonists Kalantzi KI, et al. Expert Rev Clin Pharmacol. 2012;5:
9 Patient classification by CYP2C19 genotype Ahmad T, et al. Nat. Rev. Cardiol. 8, (2011)
10 CYP2C19*2 Allelic Variant and MACE TRITON-TIMI 38 Analysis; Clopidogrel in ACS Patients 12.1 Carriers Non-carriers * Death from cardiovascular causes, myocardial infarction, or stroke P= Definite+or+Probable+Stent+Thrombosis+(%) 2 1 Carriers Non-carriers P= Days After Randomization Days After Randomization Mega JL et al. N Engl J Med. 2009;360:
11 Relation of CYP2C19 loss-of-function carrier status to clinical outcomes in clopidogrel trials
12 JAMA, December 28, 2011 Vol 306, No. 24 Conclusion: Although there was an association between the CYP2C19 genotype and clopidogrel responsiveness, overall there was no significant association of genotype with CV events
13 ELEVATE-TIMI patients with stable CVD On-Treatment Platelet Reactivity Across Genotype and Clopidogrel Daily Dose Mega JL, et al. JAMA 2011;306(20):
14 Variability in response to thienopyridine platelet inhibition Ahmad T, et al. Nat. Rev. Cardiol. 8, (2011)
15 Genotype and clinical outcomes The observations showing an association between CYP2C19 genotype and clinical outcomes during clopidogrel administration are mostly derived from platelet-oriented ischaemic events: PCIrelated MI or stent thrombosis The influence of CYP2C19 genotype on ischaemic event occurrence has not been demonstrated in non-pci patients Genotyping may be more relevant in clopidogrel naive patients to be treated with PCI to determine the optimal initial antiplatelet treatment strategy
16 Εργαστηριακή διερεύνηση της αποτελεσµατικότητας
17 Flow Cytometer (FACSCalibur) Optical Lumi-Aggregometer VerifyNow Μultiple electrode platelet aggregometer Haemoscope TEG PFA-100
18 Prasugrel Inhibition of Platelet Aggregation After Loading Dose in Patients With Elective PCI 100 IPA % (20 µm ADP) *** *** *** Prasugrel 60 mg Clopidogrel 600 mg *** 20 ***p< Prasugrel vs. Clopidogrel IPA=inhibition of platelet aggregation; PCI=Percutaneous coronary intervention Hours Wiviott SD et al. Circulation 2007;116(25):
19 Ticagrelor Inhibition of platelet reactivity IPA, inhibition of platelet aggregation Gurbel PA, et al. Circulation. 2009;120: Gurbel PA, et al. Circulation 2010;121;
20 The POPular study First head to head comparison multiple platelet function tests in predicting thrombotic and bleeding events Survival free from Primary Endpoint (1 year) Composite of death, non fatal MI, definite stent thrombosis and stroke
21 The POPular study None of the tests able to discriminate between patients with and without TIMI major and minor bleeding
22 ARMYDA-PROVE Study Distribution of Platelet Reactivity Mangiacapra F, et al. J Am Coll Cardiol Intv. 2012;5:281 9
23 Is Tailored Treatment a Solution to Overcome HTPR?
24 GRAVITAS Study Design DES, drug-eluting stents; PCI, percutaneous coronary intervention; PRU, P2Y12 reaction units. *Peri-PCI clopidogrel per protocol-mandated criteria to ensure steady-state at hrs. Placebo-controlled; all patients received aspirin ( mg daily). Price MJ, et al. JAMA. 2011;305:
25 GRAVITAS Pharmacodynamic effect of high vs standard clopidogrel dose in patients with HTPR 230 PRU P<0.001 P<0.001 Price MJ, et al. JAMA. 2011;305(11):
26 GRAVITAS Primary Endpoint: CV Death, MI, Stent Thrombosis Price MJ, et al. JAMA. 2011;305(11):
27 Stable CAD and clinical indication for PCI Trenk D, et al. JACC. 2012;59;
28 TRIGGER-PCI Stable CAD and clinical indication for PCI Trenk D, et al. JACC. 2012;59;
29 TRIGGER-PCI Trenk D, et al. JACC. 2012;59;
30 TRIGGER-PCI Trenk D, et al. JACC. 2012;59; TRIGGER-PCI
31 TRILOGY ACS Platelet Function Substudy Prasugrel vs Clopidogrel for UA-NSTEMI without Revascularization 30 mg of prasugrel LD or 300 mg of clopidogrel LD 10 or 5 mg/d prasugrel or 75 mg/d clopidogrel Gurbel PA, et al. JAMA. 2012; 308:
32 TRILOGY ACS Prasugrel vs Clopidogrel for UA-NSTEMI without Revascularization 30 mg of prasugrel LD or 300 mg of clopidogrel LD 10 or 5 mg/d prasugrel or 75 mg/d clopidogrel Efficacy Outcomes at 30 Months Roe MT, et al. N Engl J Med 2012
33 ARCTIC Study 2440 patients scheduled for coronary stenting HTPR to Aspirin or Clopidogrel Conventional Treatment Monitoring (N = 1227) (N = 1213) 1 year of follow-up Collet J-P, et al. NEJM 2012
34 ARCTIC Study ARCTIC Study does not support the routine use of platelet-function testing in patients undergoing coronary stenting Collet J-P, et al. NEJM 2012
35 Gregg W. Stone, et al.
36
37 ADAPT-DES: Stent thrombosis (definite or probable) according to post-pci PRU Stent thrombosis (def/prob) (%) 2 1 PRU >208 (n=3610) PRU 208 (n=4839) HR [95%CI] = 2.54 [1.55, 4.16] P= % 0.5% Number at risk: PRU > 208 PRU Months
38 ADAPT-DES: MI and major bleeding according to post-pci PRU 10 Myocardial infarction HR [95%CI] = 1.47 [1.15, 1.87] P= Major bleeding HR [95%CI] = 0.83 [0.69, 0.99] P=0.04 PRU >208 (n=3610) PRU 208 (n=4839) PRU >208 (n=3610) PRU 208 (n=4839) 5 3.9% 2.7% 5 6.7% 5.6% Months Months
39 ADAPT-DES: Multivariable propensity score adjusted risk of VerifyNow PRU >208 for subsequent 1-year adverse events (n=8,583) Event Adj HR [95%CI] P value ST, def/prob 2.49 [1.43, 4.31] Definite 3.05 [1.62, 5.75] MI 1.42 [1.09, 1.86] 0.01 Major bleeding 0.73 [0.61, 0.89] Death, all-cause 1.20 [0.85, 1.70] 0.30 Variables in model: age, gender, diabetes, hypertension, hyperlipidemia, current smoking, prior MI, CKD, stable vs NSTEMI vs STEMI, hemoglobin, WBC, platelet count, creatinine clearance, MVD, premature DAPT discontinuation within 6 months, PRU >208 (forced in), ARU >550 (forced in)
40 ADAPT-DES: Multivariable propensity score adjusted risk of VerifyNow ARU >550 for subsequent 1-year adverse events (n=8,583) Event Adj HR[95%CI] P value ST, def/prob 1.46 [0.58, 3.64] Definite 1.60 [0.57, 4.48] 0.37 MI 0.81 [0.46, 1.42] 0.46 Major bleeding 0.65 [0.43, 0.99] 0.04 Death, all-cause 1.42 [0.83, 2.43] 0.20 Variables in model: age, gender, diabetes, hypertension, hyperlipidemia, current smoking, prior MI, CKD, stable vs NSTEMI vs STEMI, hemoglobin, WBC, platelet count, creatinine clearance, MVD, premature DAPT discontinuation within 6 months, PRU >208 (forced in), ARU >550 (forced in)
41 ADAPT-DES: Conclusions and Implications On-treatment hyporesponsiveness to clopidogrel after DES was an independent predictor of 1-year ST and MI, but was also protective against major bleeding, both of which were strongly related to mortality On-treatment clopidogrel hypo-responsiveness was not independently predictive of 1-year mortality Hyporesponsiveness to Aspirin was unrelated to ST, MI or death, but may be related to bleeding, questioning the utility of aspirin in pts treated with DES
42 Clopidogrel Responsiveness Study (300 mg) A Fingerprint of Clopidogrel Response Variability 2 Hours 24 Hours 24 Resistance = 63% 20 Resistance Resistance = 31% Patients (%) (-20,-10] (-30,-20] (-10,0] (0,10] (10,20] (20,30] (30,40] (40,50] (50,60] >60-30 (-20,-10] (-30,-20] (-10,0] (0,10] (10,20] (20,30] (40,50] (30,40] (50,60] >60 5 Days 30 Days 22 Resistance Resistance = 31% 28 Resistance = 15% Patients (%) Resistance -10 (-10,0] (0,10] (10,20] (20,30] (30,40] (40,50] (50,60] >60-30 (-20,-10] (0,10] (20,30] (40,50] >60 Δ Aggregation (%) (-30,-20] (-10,0] (10,20] (30,40] Δ Aggregation (%) (50,60] Gurbel PA et al. Circulation. 2003;107:
43 VASP analysis 5-days 1-month Responders Non-responders 22,2% CHS 11,1% 77,8% 88,9% Tsoumani M, et al. Expert Opin Pharmacother. 2012; 13:
44 The clopidogrel-induced platelet inhibition are improved in clopidogrel non-responders at 30 days of therapy with 75 mg/day Responders Nonresponders Kalantzi KI, et al. J Thromb Haemost. 2011;9: Kalantzi KI, et al. Platelets. 2012; In Press
45 Conclusion Validation of laboratory monitoring of antiplatelet treatment Identification of the most accurate laboratory test Standardization of pre-analytical and analytical variables Identification of universal cut-off values The Platelet Function Tests may be useful In high risk patients for stent thrombosis or bleeding CKD DM Multivessel stenosis Genotyping and/or platelet function testing may be considered in selected cases (Class IIb-ESC Guidelines 2011 NSTEMI)
46
47 CURRENT OASIS 7 Τhe use of a double dose of clopidogrel for 7 days, as compared with the standard dose, did not reduce the incidence of the primary outcome of CV death, MI or stroke at 30 days The CURRENT OASIS 7 Investigators. NEJM. 2010;363:
48 CURRENT OASIS 7 In patients undergoing PCI for ACS, a 7-day double-dose clopidogrel regimen was associated with a reduction in CV events and stent thrombosis compared with the standard dose. A double-dose clopidogrel regimen can be considered for all patients with ACS treated with an early invasive strategy and intended early PCI Mehta SR. Lancet. 2010; 376:
New insights in stent thrombosis: Platelet function monitoring. Franz-Josef Neumann Herz-Zentrum Bad Krozingen
New insights in stent thrombosis: Platelet function monitoring Franz-Josef Neumann Herz-Zentrum Bad Krozingen New insights in stent thrombosis: Platelet function monitoring Variability of residual platelet
More informationDo We Need Platelet Function Assays?
Do We Need Platelet Function Assays? Matthew J. Price MD Director, Cardiac Catheterization Laboratory Scripps Clinic, La Jolla, CA The Antiplatelet Effect of Clopidogrel Varies Widely Among Individuals
More informationClopidogrel Use in ACS and PCI: Clinical Trial Update
Clopidogrel Use in ACS and PCI: Clinical Trial Update Matthew J. Price MD Director, Cardiac Catheterization Laboratory, Scripps Clinic, La Jolla, CA Assistant Professor, Scripps Translational Science Institute
More informationand Ticagrelor Professor of Medicine (Cardiology), Georgetown University Associate Director, Division of Cardiology, Washington Hospital Center
Role of Genotyping and Point-of-Care of Testing in Clopidogrel, Prasugrel, and Ticagrelor Ron Waksman, MD Ron Waksman, MD Professor of Medicine (Cardiology), Georgetown University Associate Director, Division
More informationSurveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management
Surveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management Jeffrey S Berger, MD, MS Assistant Professor of Medicine and Surgery Director of Cardiovascular Thrombosis Disclosures
More informationPlatelet function testing to guide P2Y 12 -inhibitor treatment in ACS patients after PCI: insights from a national program in Hungary
Platelet function testing to guide P2Y 12 -inhibitor treatment in ACS patients after PCI: insights from a national program in Hungary Dániel Aradi MD PhD Interventional Cardiologist Assistant professor
More informationPoint-of-Care Genetic Testing for Tailored Anti-Platelet Therapy Ready for Prime Time?
Point-of-Care Genetic Testing for Tailored Anti-Platelet Therapy Ready for Prime Time? Robert G. Wilkins, M.D., F.A.C.C., F.S.V.M New Cardiovascular Horizons May 29, 2015 No Disclosures Dual Anti-Platelet
More informationSpeaker s name: Thomas Cuisset, MD, PhD
Speaker s name: Thomas Cuisset, MD, PhD X I have the following potential conflicts of interest to report: x Consulting: Daiichi Sankyo, Eli Lilly Employment in industry Stockholder of a healthcare company
More informationStephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland
Advances in Antiplatelet Therapy in PCI and ACS Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland Targets for Platelet
More informationSession Objectives. Clopidogrel Resistance. Clopidogrel (Plavix )
Session Objectives New Antithrombotics and Real Time Genetic Testing: Their Role in the Vascular Patient Margaret C. Fang, MD, MPH Associate Professor of Medicine Division of Hospital Medicine Medical
More informationWhy and How Should We Switch Clopidogrel to Prasugrel?
Case Presentation Why and How Should We Switch Clopidogrel to Prasugrel? Shaul Atar Western Galilee Medical Center Nahariya, ISRAEL Case Description A 67 Y. Old Pt. admitted to IM with anginal CP. DM,
More informationClopidogrel vs New Antiplatelet Therapy (Prasugrel) Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität München, Germany
Clopidogrel vs New Antiplatelet Therapy () Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität München, Germany Seoul, April 3, 21 Dual Antiplatelet Therapy for Stenting MACE, % 12 1 8 6 In
More informationΔοκιμασίες λειτουργικότητας αιμοπεταλίων και PCI
Δοκιμασίες λειτουργικότητας αιμοπεταλίων και PCI Ομάδες Εργασίας Φεβρουάριος 2016 Ξανθοπούλου Ιωάννα Καρδιολόγος Επιμ Β ΠΓΝΠατρών Nothing to disclose Platelet function testing (PFT) is helpful in identifying
More informationPersonalized Antiplatelet Therapy: State of the Art
Personalized Antiplatelet Therapy: State of the Art Paul A. Gurbel, M.D. Sinai Center for Thrombosis Research Associate Professor of Medicine Johns Hopkins University School of Medicine Baltimore, Maryland,
More informationACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club 1 Optimising Crossover from Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome [CAPITAL OPTI-CROSS] Monique Conway, PharmD, BCPS PGY-2 Cardiology Pharmacy
More informationOptimal Duration and Dose of Antiplatelet Therapy after PCI
Optimal Duration and Dose of Antiplatelet Therapy after PCI Donghoon Choi, MD, PhD Severance Cardiovascular Center Yonsei University College of Medicine Optimal Duration of Antiplatelet Therapy after PCI
More informationתרופות מעכבות טסיות חדשות ד"ר אלי לב מנהל שרות הצנתורים ח השרון מרכז רפואי רבין
תרופות מעכבות טסיות חדשות ד"ר אלי לב מנהל שרות הצנתורים ח השרון בי""י מרכז רפואי רבין 1. Why should clopidogrel be replaced? 2. Prasugrel 3. Ticagrelor 4. Conclusions CURE TRIAL ACS pts 20 % reduction
More informationWhat hematologists should know about VerifyNow
What hematologists should know about VerifyNow Hematology fellows conference 12/13/2013 Presenter: Christina Fitzmaurice, MD, MPH Discussant: Daniel Sabath, MD, PhD HMC consult patient 54 yo woman admitted
More informationTicagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial
compared with clopidogrel in patients with acute coronary syndromes the PLATO trial August 30, 2009 at 08.00 CET PLATO background In NSTE-ACS and STEMI, current guidelines recommend 12 months aspirin and
More informationClopidogrel Response Variability and Platelet Function Testing: Should Routine Practice Be Changed in Interventional Cardiology?
Clopidogrel Response Variability and Platelet Function Testing: Should Routine Practice Be Changed in Interventional Cardiology? Matthew J. Price MD, FACC Director, Cardiac Catheterization Laboratory Scripps
More informationΜιχάλης Χαμηλός, MD, PhD, FESC
Αντίσταση στα αντιαιμοπεταλιακά. Πως μετράται, πότε πρέπει να εκτιμάται, και πως αντιμετωπίζεται Μιχάλης Χαμηλός, MD, PhD, FESC Πανεπιστημιακό Νοσοκομείο Ηαρκλείου Disclosures Speakers Honoraria: Astra
More informationWhat oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor
76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class
More informationQuale terapia antiaggregante nello STEMI? Prasugrel vs ticagrelor
Quale terapia antiaggregante nello STEMI? Prasugrel vs ticagrelor Leonardo Bolognese Cardiovascular Department, Arezzo, Italy Platelet Reactivity in Patients with STEMI Undergoing Primary PCI Campo G et
More informationThe Pharmacogenetics of Clopidogrel
The Pharmacogenetics of Clopidogrel CANNeCTIN Cutting-Edge Pharmacogenetics Symposium May 22, 2009 Marc S. Sabatine, MD, MPH Investigator, TIMI Study Group Associate Physician, Cardiovascular Division,
More informationDrug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis Alaide Chieffo
Drug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis 11.45-12.07 Alaide Chieffo San Raffaele Scientific Institute, Milan, Italy Historical Perspective 25 20 15 10 5 0 Serruys 1991
More informationAdjunctive Antithrombotic for PCI. SCAI Fellows Course December 9, 2013
Adjunctive Antithrombotic for PCI SCAI Fellows Course December 9, 2013 Theodore A Bass, MD FSCAI President SCAI Professor of Medicine, University of Florida Medical Director UF Shands CV Center,Jacksonville
More informationDisclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None
SCAI Fellows Course December 10, 2013 Disclosures Theodore A. Bass MD, FSCAI The following relationships exist related to this presentation None Current Controversies on DAPT in PCI Which drug? When to
More informationDECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck.
DECLARATION OF CONFLICT OF INTEREST Lecture fees: AstraZeneca, Ely Lilly, Merck. Risk of stopping dual therapy. S D Kristensen, FESC Aarhus Denmark Acute coronary syndrome: coronary thrombus Platelets
More informationP2Y 12 blockade. To load or not to load before the cath lab?
UPDATE ON ANTITHROMBOTICS IN ACUTE CORONARY SYNDROMES P2Y 12 blockade. To load or not to load before the cath lab? Franz-Josef Neumann Personal: None Institutional: Conflict of Interest Speaker honoraria,
More informationPrasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center
Prasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center Hospitalizations in the U.S. Due to ACS Acute Coronary Syndromes
More informationPrasugrel: Son of Clopidogrel or Distant Cousin? Disclosures. Objectives
Prasugrel: Son of Clopidogrel or Distant Cousin? By John J. Bon, Pharm.D., BCPS Lead Clinical Pharmacist, Critical Care Summa Health System Disclosures I have no actual or potential conflict of interest
More informationGENNARO SARDELLA MD, FACC,FESC
PhaRmacodynamic Effects of Switching therapy in PCI patients with high on Treatment platelet reactivity and genotype variation: high Clopidogrel dose versus Prasugrel (RESET GENE Study). (ClinicalTrials.gov
More informationDual Antiplatelet Therapy Made Practical
Dual Antiplatelet Therapy Made Practical David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management Clinical Associate Professor
More informationΠΑΝΕΠΙΣΤΗΜΙΟ ΙΩΑΝΝΙΝΩΝ
ΠΑΝΕΠΙΣΤΗΜΙΟ ΙΩΑΝΝΙΝΩΝ ΕΡΕΥΝΗΤΙΚΟ ΚΕΝΤΡΟ ΑΘΗΡΟΘΡΟΜΒΩΣΗΣ Σημαντικές Εξελίξεις στη Θρόμβωση 2014 2015 TRA 2P TIMI 50 και TRACER Substudies ΚΑΛΑΝΤΖΗ ΚΑΛΛΙΡΡΟΗ Καρδιολόγος ιδάκτωρ Ιατρικής Σχολής Πανεπιστημίου
More informationMONITORAGGIO DELLA FUNZIONE PIASTRINICA DURANTE TERAPIA CON TIENOPIRIDINE
MONITORAGGIO DELLA FUNZIONE PIASTRINICA DURANTE TERAPIA CON TIENOPIRIDINE Rossella Marcucci 30 novembre 2013 CardioLucca 2013 CLOPIDOGREL: A MODEL FOR PERSONALIZED MEDICINE High on-treatment platelet reactivity
More informationWhich drug do you prefer for stable CAD? - P2Y12 inhibitor
Which drug do you prefer for stable CAD? - P2Y12 inhibitor Jung Rae Cho, MD, PhD Cardiovascular Division, Department of Internal Medicine Kangnam Sacred Heart Hospital, Hallym University Medical Center,
More informationLearning Objectives. Epidemiology of Acute Coronary Syndrome
Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet
More informationOptimal antiplatelet and anticoagulant therapy for patients treated in STEMI network
Torino 6 Joint meeting with Mayo Clinic Great Innovation in Cardiology 14-15 Ottobre 2010 Optimal antiplatelet and anticoagulant therapy for patients treated in STEMI network Diego Ardissino Ischemic vs
More informationWhen and how to combine antiplatelet agents and anticoagulant?
When and how to combine antiplatelet agents and anticoagulant? Christophe Beauloye, MD, PhD Head, Division of Cardiology Cliniques Universitaires Saint-Luc Brussels, Belgium Introduction Anticoagulation
More informationAdjunctive Antithrombotic for PCI. SCAI Fellows Course December 8, 2014
Adjunctive Antithrombotic for PCI SCAI Fellows Course December 8, 2014 Theodore A Bass, MD FSCAI Immediate Past-President SCAI Professor of Medicine, University of Florida Medical Director UF Health CV
More informationOptimal lenght of DAPT in different clinical scenarios
Optimal lenght of DAPT in different clinical scenarios After PCI with DES in the light of recent and ongoing studies Dr Grégoire Rangé / CH Chartres / France DAPT duration depend on the evolution of risk
More informationControversies in PCI A young cardiologist s perspective
Controversies in PCI A young cardiologist s perspective Antiplatelet Tx, PLT function monitoring should be mandatory CONTRA M. Valgimigli, MD, PhD Ferrara, Italy Euro-PCR Session @ ESC August 30th 2010,
More informationΠροβληματισμοι στην χρηση αντιαιμοπεταλιακων στα οξέα ισχαιμικά σύνδρομα
Α ΚΑΡΔΙΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΚΑΙ ΟΜΩΝΥΜΟ ΕΡΓΑΣΤΗΡΙΟ ΙΑΤΡΙΚΗ ΣΧΟΛΗ ΠΑΝΕΠΙΣΤΗΜΙΟΥ ΑΘΗΝΩΝ ΙΠΠΟΚΡΑΤΕΙΟ ΓΕΝΙΚΟ ΝΟΣΟΚΟΜΕΙΟ ΑΘΗΝΩΝ Διευθυντής: Καθηγητής ΔΗΜΗΤΡΙΟΣ ΤΟΥΣΟΥΛΗΣ Προβληματισμοι στην χρηση αντιαιμοπεταλιακων
More informationOn admission Acute extensive anterior STEMI
Mr B 52 years old male Smoker No prior known CAD Presents with 1 hour intermittent crushing retrosternal chest pain Transferred by MICU directly to CCU (ASA, Heparin) On admission Intense pain, diaphoretic
More informationOral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death!
Oral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death! Robert C. Welsh, MD, FRCPC Associate Professor of Medicine Director, Adult Cardiac Catheterization
More informationUpdated and Guideline Based Treatment of Patients with STEMI
Updated and Guideline Based Treatment of Patients with STEMI Eli I. Lev, MD Director, Cardiac Catheterization Laboratory Hasharon Hospital, Rabin Medical Center Associate Professor of Cardiology Tel-Aviv
More informationINDIVIDUALIZED MEDICINE
CENTER FOR INDIVIDUALIZED MEDICINE Clopidogrel Pharmacogenetics Can We Impact Clinical Practice? Michael E. Farkouh, MD, MSc Peter Munk Cardiac Centre University of Toronto Naveen Pereira MD Mayo Clinic
More informationMeasurement of Antiplatelet Therapeutic Efficacy
Measurement of Antiplatelet Therapeutic Efficacy Bonnie H. Weiner MD MSEC MBA FSCAI FACC FAHA Professor of Medicine Director, Interventional Cardiology Research St Vincent Hospital Worcester MA Disclosure
More informationΔιάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά
Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά International ACS guidelines: Recommendations on duration of dual
More informationΚωνσταντίνος Π. Τούτουζας Επ. Καθηγηηής Καρδιολογίας. A Πανεπιζηημιακή Καρδιολογική Κλινική, Ιπποκράηειο Νοζοκομείο
Κωνσταντίνος Π. Τούτουζας Επ. Καθηγηηής Καρδιολογίας A Πανεπιζηημιακή Καρδιολογική Κλινική, Ιπποκράηειο Νοζοκομείο Europe* 2001 2011 Incident MI 291,100 327,700 US 2001 2011 Incident MI 405,100 485,200
More informationBalancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients
SYP.CLO-A.16.07.01 Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients dr. Hariadi Hariawan, Sp.PD, Sp.JP (K) TOPICS Efficacy Safety Consideration from Currently Available Antiplatelet Agents
More informationACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium
ACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium 4/14/2011 Cumulative death rates in 3721 ACS patients from UK and Belgium at ± 5 year (GRACE) 25 20 15 19% TOTAL 14%
More informationPlatelet Function Testing: Which Test, and How to Apply? - Current Limitations and Future Perspectives - Young-Hoon Jeong, M.D., Ph.D.
Platelet Function Testing: Which Test, and How to Apply? - Current Limitations and Future Perspectives - Young-Hoon Jeong, M.D., Ph.D. Director, Clinical Trial Center, Gyeongsang National University Hospital;
More informationAntiplatelet Therapy: Current Recommendations for Choice of Agent and Concurrent Therapy with Warfarin and Novel Oral Anticoagulants
Antiplatelet Therapy: Current Recommendations for Choice of Agent and Concurrent Therapy with Warfarin and Novel Oral Anticoagulants S. Hinan Ahmed, MD Anti-platelet Therapy: Simple Answer Bare metal stent
More informationAntiplatelet therapy in ACS/PCI. Thomas Cuisset, CHU Timone, Marseille DIU Cardiologie Interventionnelle Paris, Janvier 2013
Antiplatelet therapy in ACS/PCI Thomas Cuisset, CHU Timone, Marseille DIU Cardiologie Interventionnelle Paris, Janvier 2013 Oral Antiplatelet therapy in ACS/PCI Most Challenging Questions in Nov. 2012
More informationJOINT MEETING OF CORONARY REVASCULARIZATION 2014 TIONG LEE LEN SENIOR RESEARCH PHARMACIST CLINICAL RESEARCH CENTER, SARAWAK GENERAL HOSPITAL
The Effect of Non Steady State and Steady State Clopidogrel Carboxylic Acid Plasma Concentration on Clopidogrel Responsiveness in Patients Planned For Percutaneous Coronary Intervention JOINT MEETING OF
More informationAntiplatelet agents treatment
Session III Comprehensive management of diabetic patients Antiplatelet agents treatment Chonnam National University Hospital Department of Internal Medicine Dong-Hyeok Cho CONTENTS Introduction Prothrombotic
More informationDual Oral Antiplatelet Therapy for ACS: Improving Standards of Care to Optimize Outcomes
Agenda Welcome and Introduction Pathophysiology of ACS Is Aspirin Enough? Overview of Antiplatelet Agents Clopidogrel Prasugrel Ticagrelor New Guideline Recommendations for Dual Antiplatelet Therapy in
More informationJuly ACCP Cardiology PRN Journal Club 7/23/2018
July ACCP Cardiology PRN Journal Club 7/23/2018 Dr. Michael Plazak Dr. Michael Plazak is a PGY2 Cardiology Pharmacy Resident at the University of Maryland School of Pharmacy. He graduated from the University
More informationTim Henry, MD Director, Division of Cardiology Professor, Department of Medicine Cedars-Sinai Heart Institute
Tim Henry, MD Director, Division of Cardiology Professor, Department of Medicine Cedars-Sinai Heart Institute Implications of Pre-loading on Patients Undergoing Coronary Angiography Angiography Define
More informationPrasugrel a step ahead in antiplatelet therapy
Prasugrel a step ahead in antiplatelet therapy VS Srinath, MD (Med), DNB (Cardiology) The burden of atherosclerotic disease in the United States and across the world is vast. Although the symptoms of atherosclerosis
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST How to manage antiplatelet treatment in patients with diabetes in acute coronary syndrome Lars Wallentin Professor of Cardiology, Chief Researcher Cardiovascular Science
More informationAntiplatelet Therapy: how, why, when? For Coronary Stenting
Antiplatelet Therapy: how, why, when? For Coronary Stenting Dominick J. Angiolillo, MD, PhD, FACC, FESC, FSCAI Director of Cardiovascular Research Associate Professor of Medicine University of Florida
More informationΠεριφερική Αρτηριακή Νόσος Νόσος Καρωτίδων
Νεώτερα δεδομένα στην αντιαιμοπεταλιακή αγωγή που θα επηρεάσουν τις μελλοντικές κατευθυντήριες οδηγίες Περιφερική Αρτηριακή Νόσος Νόσος Καρωτίδων Μιλτιάδης Ματσάγκας, MD, PhD, FEBVS Αναπληρωτής Καθηγητής
More informationΤicagrelor: Μία διαφορετική χημική κατηγορία αντιαιμοπεταλιακής θεραπείας
Τicagrelor: Μία διαφορετική χημική κατηγορία αντιαιμοπεταλιακής θεραπείας Στοιχεία από πρόσφατες μελέτες Stavros V. Konstantinides, MD, FESC Department of Cardiology Democritus University of Thrace, Greece
More informationΑντιαιμοπεταλιακη αγωγη (ποια, πο τε και για πο σο)
Αντιαιμοπεταλιακη αγωγη (ποια, πο τε και για πο σο) Dimitrios Alexopoulos, MD, FESC, FACC Cardiology Department, Patras University Hospital, Patras, Rio, Greece. Patras University Hospital I, Dimitrios
More informationRazionale ed evidenze scientifiche di Doppia Antiaggregazione Piastrinica a lungo termine nel Paziente con Sindrome Coronarica Acuta
Razionale ed evidenze scientifiche di Doppia Antiaggregazione Piastrinica a lungo termine nel Paziente con Sindrome Coronarica Acuta Giuseppe Musumeci SC Cardiologia Ospedale Santa Croce e Carle Cuneo
More informationClinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective
Clinical Seminar Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical
More informationUpdate on Antiplatelet Therapy
Update on Antiplatelet Therapy Christine Ibarra Pharm.D. PGY-1 Baptist Hospital of Miami Objectives Explain the role of antiplatelettherapy in prevention of cardiovascular events Appreciate differences
More informationRisk of GI Bleeding and Use of PPIs
Risk of GI Bleeding and Use of PPIs ESC 211 August 28, 211 Marc S. Sabatine, MD, MPH Chairman, TIMI Study Group Associate Physician, Cardiovascular Division, BWH Associate Professor of Medicine, Harvard
More informationMultiplate analyzer Cut-off-values ADPtest and ASPItest
Multiplate analyzer Cut-off-values ADPtest and ASPItest Cut-off values ADPtest The cut-off values were established in hirudin blood samples. Healthy individuals AUC (U) 1 Patient on ADP receptor antagonist
More informationReduction in Stent Thrombosis better tablets or better stents?
Reduction in Stent Thrombosis better tablets or better stents? Dr James Cotton MD FRCP Heart and Lung Centre Wolverhampton MY CONFLICTS OF INTEREST ARE Speaker Fees/Honoraria/Travel Support Lilly/Daiichi
More informationOral Antiplatelet Therapy in PCI/ACS. Dominick J. Angiolillo, MD, PhD, FACC, FESC Director of Cardiovascular Research Assistant Professor of Medicine
Oral Antiplatelet Therapy in PCI/ACS Dominick J. Angiolillo, MD, PhD, FACC, FESC Director of Cardiovascular Research Assistant Professor of Medicine Basic Concepts Thrombus Formation Two key elements:
More informationDual Antiplatelet duration in ACS: too long or too short?
Dual Antiplatelet duration in ACS: too long or too short? Leonardo Bolognese, MD, FESC, FACC Cardiovascular Department, Arezzo, Italy Paradigm Shift the ideal duration of DAPT: a moving target Early (stent-related)
More informationThrombosis Research active studies
Thrombosis Research active studies A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients With Coronary Artery Disease Undergoing PCI With CYP2C19 Loss-of-function Genotypes: A Feasibility
More informationCOME ORIENTARSI TRA I NUOVI. Maria Rosa Conte H. Mauriziano Torino
COME ORIENTARSI TRA I NUOVI ANTIPIASTRINIC I Maria Rosa Conte H. Mauriziano Torino Sulle sponde del Ticino- Novara 10 maggio 2013 NEW ORAL ANTIPLATET AGENT PRASUGREL TICAGRELOR (Cangrelor) Death/ MI/
More informationUpcoming Evidence and Practice of Optimal Antiplatelet Therapy in DES Era?
Upcoming Evidence and Practice of ptimal Antiplatelet Therapy in DES Era? Polymorphism in Metabolism of Clopidogrel and Its Clinical Implications and Management Alexandra Lansky MD Columbia University
More informationBelinda Green, Cardiologist, SDHB, 2016
Acute Coronary syndromes All STEMI ALL Non STEMI Unstable angina Belinda Green, Cardiologist, SDHB, 2016 Thrombus in proximal LAD Underlying pathophysiology Be very afraid for your patient Wellens
More informationIMMATURE PLATELETS CLINICAL USE
HAEMATOLOGY FEBRUARY 217 WHITE PAPER IMMATURE PLATELETS CLINICAL USE Identifying poor antiplatelet drug response and its risks early on Platelets are important cells for repairing endothelial lesions,
More informationCilostazol: Triple Benefits More is Better!
Cilostazol: Triple Benefits More is Better! Matthew J. Price, MD Director, Cardiac Catheterization Laboratory Scripps Clinic, La Jolla, CA Assistant Professor, Scripps Translational Science Institute,
More informationDAPT Management 2015 Michael Rinaldi, MD
DAPT Management 2015 Michael Rinaldi, MD The Sanger Heart and Vascular Institute Carolinas HealthCare System Charlotte NC Disclosures Advisory Board: Abbott, BSc Advisory Board: Abbott, BSc Speaker: Abbott,
More informationDiabetic Patients: Current Evidence of Revascularization
Diabetic Patients: Current Evidence of Revascularization Alexandra J. Lansky, MD Yale University School of Medicine University College of London The Problem with Diabetic Patients Endothelial dysfunction
More informationΣτεφανιαίος ασθενής με μη βαλβιδική Κολπική Μαρμαρυγή - Νέες στρατηγικές
4 ο ΠΑΝΕΛΛΗΝΙΟ ΑΡΡΥΘΜΙΟΛΟΓΙΚΟ ΣΥΝΕΔΡΙΟ 21-22 ΣΕΠΤΕΜΒΡΙΟΥ 2018 HILTON, ΑΘΗΝΑ Στεφανιαίος ασθενής με μη βαλβιδική Κολπική Μαρμαρυγή - Νέες στρατηγικές Ι. Κανακάκης MD, PhD Διευθυντής Αιμοδυναμικού Τμήματος
More information3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationNew antiplatelets in NSTEMI. Overview: dual anti-platelet oral therapy
Cairo, Egypt 2010 New antiplatelets in NSTEMI Steen D. Kristensen, FESC Department of Cardiology Aarhus University Hospital Skejby Denmark Overview: dual anti-platelet oral therapy Aspirin Clopidogrel
More informationAngelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationDAPT in CAD, Acute & Chronic CAD, antiplatelet therapy non-responders
DAPT in CAD, Acute & Chronic CAD, antiplatelet therapy non-responders Annual Ohio ACC Conference October 14, 2017 Ernest L. Mazzaferri Jr, MD, FACC, FSCAI Disclosures No financial disclosures related to
More informationPCI in Patients with AF Optimizing Oral Anticoagulation Regimen
PCI in Patients with AF Optimizing Oral Anticoagulation Regimen Walid I. Saliba, MD Director, Atrial Fibrillation Center Heart and Vascular Institute Cleveland Clinic 1 Epidemiology and AF and PCI AF and
More informationA PRAGMATIC RANDOMIZED TRIAL OF CYP2C19 GENOTYPING IMPLEMENTATION FOLLOWING PERCUTANEOUS CORONARY INTERVENTION (PCI)
A PRAGMATIC RANDOMIZED TRIAL OF CYP2C19 GENOTYPING IMPLEMENTATION FOLLOWING PERCUTANEOUS CORONARY INTERVENTION (PCI) Sony Tuteja, PharmD, MS Twitter @sony_tuteja Perelman School of Medicine at the University
More informationCangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015
Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015 Objectives Review the pharmacology and pharmacokinetic
More informationJoint Meeting of Coronary Revascularization 8 th to 9 th December 2017
B Joint Meeting of Coronary Revascularization 8 th to 9 th December 2017 A Novel Clinical Application Combining Genotyping and Platetlet Function Testing In Patients With Acs - A Case Series Shirley Tan
More informationΠποβλημαηιζμοί με ηην ανηιαιμοπεηαλιακή αγωγή ζηο οξύ έμθπαγμα ηος μςοκαπδίος με ανάζπαζη ηος διαζηήμαηορ ST.
Patras University Hospital Πποβλημαηιζμοί με ηην ανηιαιμοπεηαλιακή αγωγή ζηο οξύ έμθπαγμα ηος μςοκαπδίος με ανάζπαζη ηος διαζηήμαηορ ST. Dimitrios Alexopoulos, MD, FACC, FESC Cardiology Department, Patras
More informationIs Cangrelor hype or hope in STEMI primary PCI?
Is Cangrelor hype or hope in STEMI primary PCI? ARUN KALYANASUNDARAM MD, MPH, FSCAI HOPE Issues with platelet inhibition in STEMI Delayed onset In acute settings, achieving the expected antiplatelet effect
More informationAntiplatelet and Anti-Thrombotic Therapy. Ivan Anderson, MD RIHVH Cardiology
Antiplatelet and Anti-Thrombotic Therapy Ivan Anderson, MD RIHVH Cardiology Outline Anti-thrombotic therapy Risk stratification of stroke with atrial fibrillation DVT and PE treatment Pharmacology Anti-platelet
More informationISCHEMIC HEART DISEASE
ESC CONGRESS HIGHLIGHTS ISCHEMIC HEART DISEASE Francesco Cosentino (Stockholm, S) Declaration of Interest Advisory Board/Speaker: AstraZeneca, Roche, Boehringer-Ingelheim, Bristol-Myers Squibb, Merck,
More informationThe Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease
Interventional Cardiology and Cath Labs The Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease Manesh R. Patel MD Chief,
More informationAnti-platelet therapies and dual inhibition in practice
Anti-platelet therapies and dual inhibition in practice Therapeutics; Sept. 25 th 2007 Craig Williams, Pharm.D. Associate Professor of Pharmacy Objectives 1. Understand the pharmacology of thienopyridine
More informationOptimal Duration of Dual Anti- Platelet Therapy. December 19, 2015
Optimal Duration of Dual Anti- Platelet Therapy December 19, 2015 John S. MacGregor, M.D., Ph.D. Professor of Medicine University of California San Francisco Source: The New Yorker 1 Optimal Duration of
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationUpdate on Oral Antiplatelet Therapy in Coronary Artery Disease
Update on Oral Antiplatelet Therapy in Coronary Artery Disease Ty J. Gluckman, MD, FACC Providence St. Vincent Heart and Vascular Institute, Portland, Oregon Ciccarone Center for the Prevention of Heart
More information